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Abstract
Increased expression of androgen receptor (AR) in
prostate cancer (PC) is associated with transition to
androgen independence. Because the progression of
PC to advanced stages is often associated with the
loss of p53 function, we tested whether the p53 could
regulate the expression of AR gene. Here we report
that p53 negatively regulates the expression of AR
in prostate epithelial cells (PrECs). We found that in
LNCaP human prostate cancer cells that express the
wild-type p53 and AR and in human normal PrECs,
the activation of p53 by genotoxic stress or by inhibi-
tion of p53 nuclear export downregulated the expres-
sion of AR. Furthermore, forced expression of p53 in
LNCaP cells decreased the expression of AR. Con-
versely, knockdown of p53 expression in LNCaP cells
increased the AR expression. Consistent with the nega-
tive regulation of AR expression by p53, the p53-null
HCT116 cells expressed higher levels of AR compared
with the isogenic HCT116 cells that express the wild-
type p53. Moreover, we noted that in etoposide treated
LNCaP cells p53 bound to the promoter region of the
AR gene, which contains a potential p53 DNA-binding
consensus sequence, in chromatin immunoprecipitation
assays. Together, our observations provide support for
the idea that the loss of p53 function in prostate cancer
cells contributes to increased expression of AR.
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Introduction
The androgen–androgen receptor (AR) signaling plays an
important role in proper development and function of male
reproductive organs, such as prostate and epididymis
[1–4]. Furthermore, androgen–AR signaling plays a key
role in nonreproductive organs, such as muscle, hair fol-
licles, and brain. Abnormalities in the androgen–AR sig-
naling pathway in humans have been linked to certain
diseases, such as male infertility, Kennedy’s disease, and
prostate cancer (PC) [1,2].
AR signaling is central to the development of PCs and to its
response to hormone withdrawal therapy [1,4,5]. Studies have
indicated that AR continues to be expressed in androgen-
independent tumors and that alterations in the AR signaling
contribute to the progression of PC to advanced stages, includ-
ing androgen independence [1,4]. Moreover, studies have
revealed that a subset of androgen-independent PCs express
increased levels of AR [4,6]. However, molecular mechanisms
that contribute to the increased expression of AR in PC cells
remain unknown.
Genetic alterations in the p53 pathway contribute to more
than 50% human cancers [7–9]. The p53 is a transcription
factor that is activated in cells in response to certain stimuli,
such as DNA damage, hypoxia, oxidative stress, or other
cellular stress [10–13]. The activation of p53 in cells results
in binding of p53 to its DNA-binding consensus sequence that
is present in its target genes. The binding of p53 to its target
genes is known to result in either transcriptional activation of
genes, such as p21CIP1 and Gadd45, or transcriptional repres-
sion of genes, such as Bcl2, MAP4, and SAK [14–16]. The
p53-regulated genes encode proteins that mediate tumor sup-
pressor function of p53 by inducing cell growth arrest, apop-
tosis, or senescence [9,15,17].
Studies have suggested that mutations in the p53 gene are
associated with human PC progression [18–20]. Moreover,
mutations in p53 may be a poor prognostic factor in PC [19,21].
Consistent with the above observations, it is interesting to note
that the majority of metastatic PC–derived cell lines (seven of
eight) described in the literature [22] harbor mutations of AR
and/or p53. These observations suggest an important func-
tional relationship between the p53 and AR in the progression
of human PC.
Because p53 and AR functionally interact with each other [23,
24], we investigated whether p53 could regulate the expression
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of AR. We provide evidence that p53 negatively regulates the
expression of AR in human prostate epithelial cells (PrECs).
Materials and Methods
Cell Lines, Culture Conditions, and Treatments
Saos-2 human osteosarcoma cells stably expressing the
temperature-sensitive mutant (Val138 mutation) of human
p53 (with Arg-72; see Dumont et al. [25]); were generously
provided by Dr. MaureenMurphy (Fox Chase Cancer Center,
Philadelphia, PA). As indicated, these cells were incubated
at 39jC (favoring p53 mutant conformation) or 32jC (favor-
ing p53 wild-type conformation).
HCT116 p53 wild-type and p53 knockout colorectal car-
cinoma cells [26] were generously provided by Dr. Bert
Vogelstein (John Hopkins University Howard Hughes Medi-
cal Institute and Kimmel Cancer Center, Baltimore, MD).
Saos-2 osteosarcoma and LNCaP human prostate carcinoma
cell lines were purchased from the American Type Culture
Collection (Manassas, VA). Saos-2 and HCT116 cell lines
were maintained in RPMI-1640 and DMEM (high glucose)
culture media (Invitrogen, Carlsbad, CA) supplemented with
10% (v/v) fetal bovine serum and antibiotics, respectively.
LNCaP cells were maintained in 1:1 ratio of RPMI-1640 and
DMEM culture media. Human normal PrECs were purchased
(in culture) from Cambrex (Walkersville, MD) and maintained
in prostate epithelial basal medium (PrEBM) with supple-
ments and growth factors as suggested by the supplier. Sub-
confluent cultures of LNCaP cells were treated with etoposide
(Calbiochem, San Diego, CA), doxorubicin (Sigma, St Louis,
MO), or leptomycin-B (LMB) in ethanol (Calbiochem) at the
indicated concentrations and duration. Subconfluent cultures
of PrECs were treated with either doxorubicin or LMB at the
indicated concentrations and duration.
Knockdown of p53 Expression
Subconfluent cultures of LNCaP cells were transfected
with a pool of p53 small interfering RNA (siRNA) (cat #
M-003557-00-05; Dharmacon, Denver, CO) or a nonspecific
control siRNA (cat # D-001206-02-05; Dharmacon) as rec-
ommended by the manufacturer using Lipofectamine (Invitro-
gen) transfection agent and as described previously [27]. Sixty
hours posttransfection, cells were processed for immunoblot
analysis.
Nucleofections
LNCaP cells were nucleofected with 2 mg of pCMV-p53
(Val135) plasmid, encoding a temperature-sensitive mutant
of human p53, or pCMV-p53 plasmid that encodes the
wild type p53. Nucleofector-II device (Amaxa Biosystems,
Natthermannalle 1, Germany) and nucleofection kit were
used as suggested by the supplier. Twenty-four hours after
nucleofection, cells were subjected to immunoblot analysis.
Immunoblot Analysis and Antibodies
Total cell lysates were prepared and subjected to immu-
noblot analysis as described previously [28]. Antibodies spe-
cific for p53 (sc-126), p21CIP1 (sc-397), AR (cat # sc-816,
sc-7305), and GAPDH (sc-32233) were purchased from
Santa Cruz Biotech (Santa Cruz, CA). b-Actin antibody
(cat # 4967) was purchased from Cell Signaling Technology
(Danvers, MA). Horseradish peroxidase–conjugated sec-
ondary anti-mouse (NXA-931) and anti-rabbit (NA-934) anti-
bodies were from Amersham Biosciences (Princeton, NJ).
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from Saos-2 p53 (with Arg-72;
see Dumont et al. [25]) and LNCaP cells with a reagent
(TRIzol; Invitrogen) and processed for cDNA synthesis fol-
lowed by polymerase chain reaction (PCR) for AR and
b-actin as described previously [29].
Reporter Assays
Luciferase reporter assays were performed as described
previously [30]. pGL-AR3.5-luc-reporter plasmid [31] was
generously provided by Dr. Alexander Chlenski (Northwestern
University, Chicago, IL). In brief, subconfluent cultures of
Saos-2 p53 Arg 72 (Saos-2Arg72) cells were transfected with
1.8 mg of AR 3.5-luc or p21-luc [32] reporter plasmid along
with 0.2 mg of pRL-TK reporter plasmid using Fugene-6 trans-
fection reagent (Rosch, Indianapolis, IN). Twenty-four hours
posttransfection, the firefly luciferase and Renilla luciferase
activities were assayed (in triplicates) using Dual-Luciferase
Reporter Assay kit (Promega, Madison, WI). When indicated,
the transfected cells weremaintained at 39jC and then shifted
to 32jC.
Chromatin Immunoprecipitation Assay
Subconfluent cultures of LNCaP cells were treated with
45 mM of etoposide (Calbiochem) for 15 hours. The amount
of 1% crosslinking mix (37% formaldehyde, 5 MNaCl, 50 mM
EGTA, 1 M Hepes) was added to LNCaP cells followed by
10-minute fixation at room temperature with gentle agitation.
The reaction was quenched with glycine at a final concen-
tration of 125 mM. After centrifugation, cell pellets were
washed twice with chilled 1 PBS. Cell pellets were lysed
in the lysis buffer (10% SDS, 0.5 M EDTA, 1 M Tris–HCl, pH
8.0, and EDTA-free protease inhibitor cocktail; Roche, India-
napolis, IN). After brief sonication of cell lysates, extracts
were subjected to immunoprecipitations. In brief, cell lysates
were incubated overnight with 4 mg of anti-p53 (sc-126;
Santa Cruz Biotech) or control anti-IgG (cat # OB02; Calbio-
chem). Immunoprecipitates were eluted with an elution buffer
(1% SDS, 100 mM NaHCO3) and 500 mg/ml proteinase K
and RNase A. The solution was incubated at 37jC for
30 minutes. Immunoprecipitated DNAwas extracted and puri-
fied with phenol–chloroform. Purified DNA was suspended
in 50 to 100 ml of sterile H2O. Polymerase chain reaction was
performed at 38 cycles and the products, i.e., input DNA and
immunoprecipitated DNA, were analyzed on 0.8% agarose
gel. The following PCR primers were used to detect an
amplification product of 1159 bp: AR (forward): 5V–CATCTGT-
GAAATAGAG CCTATCATATCCAG–3V; AR (backward): 5V–
TAACGCCTGCCTAGTGG CTTTGGAG–3V.
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Results
Expression of a Temperature-Sensitive Mutant of
p53 In Human Saos-2 Cells Downregulates the
Expression of AR
To test whether p53 could regulate the expression of AR,
we chose to use the well-characterized human osteosar-
coma Saos-2 cell system (Saos-2 cells are null for p53),
which expresses a temperature-sensitive mutant (Val135) of
p53 with the amino acid residue Arg (instead of Pro) at the
position 72 (cells indicated as SaosArg72; see Dumont et al.
[25]). Moreover, Saos-2 cells express detectable levels of AR
[33]. As shown in Figure 1A, incubation of SaosArg72 cells at
32jC for 24 hours resulted in upregulation of p21CIP1 protein,
a transcriptional target of p53 protein. Importantly, levels of
AR protein decreased measurably in extracts from SaosArg72
cells that were incubated at 32jC.
To rule out the possibility that incubation of cells at 32jC
could account for decreases in the AR protein levels (inde-
pendent of p53 expression), we also compared AR protein
levels between the parental Saos-2 cells that were incubated
at 39 or 32jC. We found no measurable difference between
AR protein levels in extracts from cells incubated at these
two different temperatures (Figure 1B).
We also noted that the steady-state levels of AR mRNA
also decreased about more than two-fold in SaosArg72 cells
after their incubation at 32jC for 24 hours (Figure 1C).
Consistent with the above observations that incubation of
SaosArg72 cells at 32jC resulted in upregulation of p21CIP1
expression and downregulation of AR expression, we noted
that incubation of SaosArg72 cells that were transfected with
p21-luc-reporter plasmid at 32jC resulted in stimulation of
the activity of reporter about eight-fold (Figure 1D). In con-
trast, incubation of SaosArg72 cells that were transfected
with AR3.5-luc-reporter plasmid at 32jC resulted in f50%
decrease in the activity of reporter in two experiments (Fig-
ure 1E ). Together, these observations suggested that the
restoration of p53 function in Saos-2 cells downregulated
the AR expression.
The p53 Expression Status In Isogenic HCT116 Cell
Lines Inversely Correlates with the Expression
Levels of AR
Our above observations that the functional activation of a
temperature-sensitive mutant of p53 in SaosArg72 cells down-
regulated the expression of AR prompted us to compare the
AR protein levels between human colorectal cancer cell line
HCT116 cells (HCT116p53+) that express the wild type p53
and isogenic HCT116 cells (HCT116p53) that are null for p53
expression [26]. Moreover, HCT116 cells express detectable
levels of AR [34]. As shown in Figure 2, we could detect
the expression of p53 in the HCT116p53+ cells, but not in
HCT116p53 cells (compare lane 1 with 2). Notably, con-
sistent with p53 expression status in these two human can-
cer cell lines, we could detect the expression of p21CIP1 in
HCT116p53+ cells, but not in HCT116p53 cells (compare
lane 1 with 2). Importantly, the expression of p53 status in
these two isogenic cell lines inversely correlated with the
Figure 1. Restoration of p53 function in human Saos-2 osteosarcoma cell line downregulates the expression of AR. (A) Subconfluent cultures of SaosArg72 cells
were incubated either at 39jC (lanes 1) or at 32jC (lane 2) for 24 hours. After incubations, total cell lysates were analyzed by immunoblot analysis using antibodies
specific to the indicated proteins. (B) Subconfluent cultures of Saos-2 cells were incubated either at 39jC (lanes 1) or at 32jC (lane 2) for 24 hours. After
incubations, total cell lysates were analyzed by immunoblot analysis using antibodies specific to the indicated proteins. (C) Subconfluent cultures of SaosArg72 cells
were incubated either at 39jC (lanes 1) or 32jC (lanes 2). Twenty-four hours after incubation, total RNA was isolated and steady-state levels of AR and actin
mRNA were analyzed by semiquantitative reverse transcription–polymerase chain reaction (RT-PCR). (D and E) Two sets of SaosArg72 cell cultures (in 60-mm
plates) were transfected with p21-luc or AR3.5-luc-reporter plasmid (1.8 g) along with pRL-TK plasmid (0.2 g; plasmids in 9:1 ratio) using Fugene-6 transfection
reagent. One set of plates for each reporter was incubated at 39jC and the other sets of plates were incubated at 32jC. Forty-four hours after incubations, cells
were processed for dual-luciferase reporter activity assays as described in the Materials and Methods section. The firefly luciferase reporter activity was normalized
to the Renilla luciferase activity to control for variations in transfection efficiencies. The luciferase activity for (C) p21-luc or (D) AR3.5-luc reporter in control cells
is shown as 1.
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expression levels of AR. These observations suggested that
the expression of functional p53 in HCT116 cells is associ-
ated with reduced or lack of AR expression.
Expression of a Temperature-Sensitive Mutant of p53
In LNCaP Cells Downregulates AR Expression
Our above observations that the expression of the func-
tional p53 in two human cancer cell lines (Saos-2 and
HCT116) inversely correlated with the expression levels of AR
prompted us to test whether the expression of a temperature-
sensitive mutant of p53 or the ectopic expression of p53 in
LNCaP PC cells that are known to express relatively high
levels of a mutant AR and detectable levels of functional p53
downregulates the AR expression. As shown in Figure 3A,
incubation of LNCaP cells that were nucleofected with a
temperature-sensitive (Val135) mutant of p53 at 32jC for 24
hours resulted in upregulation of p21CIP1 protein levels. More
importantly, the incubation of cells downregulated the en-
dogenous levels of AR protein. However, the incubation of
LNCaP cells that were nucleofected with an empty vector
(pCMV) at 32jC for 24 hours did not result in the down-
regulation of AR protein levels (data not shown). Similarly,
nucleofection of LNCaP cells with pCMV-p53 plasmid, but
not an empty pCMV vector, also resulted in the downregu-
lation of AR protein levels (Figure 3B).
Knockdown of p53 Expression In LNCaP Cells
Upregulates AR Expression
Our above observations that the expression of a tem-
perature-sensitive mutant of p53 or the ectopic expression
of p53 in LNCaP PC cells downregulated the expression
of AR prompted us to test whether knockdown of p53 in
LNCaP cells upregulates the expression of AR. As shown in
Figure 3C, knockdown of p53 in LNCaP with siRNA resulted
in >70% decreases in p53 protein levels (compare lane 2
with 1). Moreover, the knockdown resulted in >70% de-
creases in p21CIP1 protein levels and f50% increases in
Bcl2 levels, a p53-repressible gene [35]. Importantly, the
knockdown of p53 resulted inf2.5- to 3-fold increases in AR
protein levels. These observations suggested that the steady-
state levels of AR in LNCaP cells are regulated by p53.
Activation of p53 In LNCaP Cells By Doxorubicin,
Etoposide, or LMB Downregulates the AR Expression
Treatment of LNCaP cells with DNA-damaging agents,
such as doxorubicin [36] or etoposide [37], is known to ac-
tivate p53. Moreover, treatment of LNCaP with LMB, an in-
hibitor of nuclear export, is also known to activate p53 [38].
Therefore, we tested whether the activation of p53 in LNCaP
cells by DNA-damaging agents or by LMB treatment down-
regulates the expression of AR. As shown in Figure 4A,
treatment of cells with doxorubicin at the indicated concen-
tration for 18 hours resulted in stabilization of p53, which
correlated well with upregulation of p21CIP1 protein levels. Of
note, upregulation of p53 levels after doxorubicin treatment
was associated with downregulation of AR protein levels.
Figure 2. The p53 status in isogenic HCT116 cell lines inversely correlates with
the expression levels of AR. Total cell extracts prepared from subconfluent
cultures of HCT116p53+/+ (lane 1) or HCT116p53/ (lane 2) cells were analyzed
by immunoblot analysis using antibodies specific to the indicated proteins.
Figure 3. Expression levels of p53 in LNCaP cells determine the expression levels of AR. (A) LNCaP cells were nucleofected with pCMV-p53 (Val138) plasmid as
described in the Materials and Methods section. One set of nucleofected cells was incubated at 39jC (lane 1) and the other sets of cells were incubated at 32jC (lane
2) for 24 hours. Cells were harvested after 24 hours and total cell extracts were analyzed by immunoblot analysis using antibodies specific to the indicated proteins. (B)
LNCaP cells were nucleofected with pCMV (lane 1) or pCMV-p53 (lane 2) plasmid as described in the Materials and Methods section. Nucleofected cells were
incubated at 37jC for 24 hours. Total cell extracts were analyzed by immunoblot analysis using antibodies specific to the indicated proteins. (C) LNCaP cells were
transfected with either control siRNA (lane 1) or a pool of p53 siRNA (lane 2) as described in the Materials and Methods section using Lipofectamine transfection
reagent. Sixty hours after transfection of cells, total cell lysates were analyzed by immunoblot analysis using antibodies specific to the indicated proteins.
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Similarly, treatment of cells with the indicated concentration
of etoposide for 15 hours, which resulted in upregulation of
p53 and p21CIP1, was associated with downregulation of AR
protein levels. Moreover, treatment of cells with LMB at the
indicated concentration for 24 hours resulted in increases in
p53 protein levels that were associated with upregulation of
p21CIP1 protein levels. Interestingly, increases in p53 protein
levels were associated with downregulation of AR protein
(Figure 4C) and mRNA (Figure 4D) levels. Together, these
observations suggested that the activation of p53 in LNCaP
cells by treatment of cells by doxorubicin, etoposide, or LMB
resulted in downregulation of AR expression.
Activation of p53 In Normal Human PrECs By Doxorubicin
and LMB Results in Decreases in AR Levels
The above observations that the activation of p53 in LNCaP
cells by treatment of cells by doxorubicin, etoposide, or LMB
resulted in downregulation of AR expression, prompted us
to test whether the activation of p53 in normal human PrECs
also results in decreases in AR protein levels. As shown in
Figure 5A, treatment of PrECs with doxorubicin at the indi-
cated increasing concentration for 19 hours resulted in accu-
mulation of p53, which correlated with increases in p21CIP1
protein levels. Of note, increases in p53 protein levels were
associated with decreases in AR protein levels. Similarly,
the treatment of normal PrECs with LMB for 16 hours resulted
in an increase in p53 and p21CIP1 protein levels (compare
lane 2 with 1). However, the increase in p53 protein levels
was associated with the decreases in AR protein levels. To-
gether, these observations suggested that the activation of
p53 in normal PrECs also results in downregulation of AR
protein levels.
p53 Associates with the 5 V-Regulatory Region of the AR
Gene In LNCaP Cells After Etoposide Treatment
Our above observations that the activation of p53 func-
tion in Saos-2 (Figure 1B) and LNCaP (Figure 4D) cells
Figure 4. Treatment of LNCaP cells with doxorubicin, etoposide, or LMB downregulates the expression of AR. (A) Subconfluent cultures of LNCaP cells were treated
with the indicated amounts (g/ml) of doxorubicin for 18 hours. After the treatment, cell lysates were analyzed by immunoblot analysis using antibodies specific to the
indicated proteins. (B) Subconfluent cultures of LNCaP cells were treated with the indicated concentrations (M) of etoposide for 15 hours. After the treatment, cell
lysates were analyzed by immunoblot analysis using antibodies specific to the indicated proteins. (C) Subconfluent cultures of LNCaP cells were treated with the
indicated concentrations (nM) of LMB for 24 hours. After the treatment, cell lysates were analyzed by immunoblot analysis using antibodies specific to the indicated
proteins. (D) Subconfluent cultures of LNCaP cells were treated 5 (lane 2), 10 (lane 3), or 20 nM concentrations of LMB for 24 hours. As a control, cells were left
untreated (lane 1). After the treatment, total RNA was isolated and the steady state levels AR and actin mRNA were analyzed by semiquantitative RT-PCR.
Figure 5. Treatment of normal human prostate epithelial cells with doxorubicin
or LMB downregulates AR expression. (A) Subconfluent cultures of normal
PrECs were treated with the indicated amounts (g/ml) of doxorubicin for
19 hours. After the treatment, cell lysates were analyzed by immunoblot
analysis using antibodies specific to the indicated proteins. (B) Subconfluent
cultures of normal PrECs were treated with the indicated concentration (nM) of
LMB for 16 hours. After the treatment, cell lysates were analyzed by immuno-
blot analysis using antibodies specific to the indicated proteins.
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decreased the steady-state levels of AR mRNA and in
Saos-2 cells repressed the activity of AR3.5-luc reporter
prompted us to search for a potential p53 DNA–binding site
consensus sequence in the 5V-regulatory region of AR gene.
Our search identified a single potential p53 DNA–binding
site (nucleotides 5290–5309; GenBank accession number
X78592) in the 5V-regulatory region of the human AR gene
(Figure 6A). This potential p53 DNA–binding site is located
469 bp upstream to the mRNA start site in the promoter
region of the human AR gene (Figure 6B). After localization
of a potential p53 DNA–binding site in the promoter region
of AR gene, we sought to determine whether p53 associates
with the 5V-regulatory region of AR gene. As shown in Fig-
ure 6C, we were unable to detect any association of p53
protein in control untreated LNCaP cells with the 5V-regulatory
region of AR gene in chromatin immunoprecipitation assays.
However, treatment of LNCaP cells with etoposide, which up-
regulated p53 protein levels (Figure 4B), resulted in an as-
sociation of p53 protein with the regulatory region (compare
lane 7 with 6) of the AR gene. Together, these observations
indicated that the activation of p53 in LNCaP cells with
etoposide, which resulted in downregulation of AR expres-
sion, was associated with the binding of p53 protein to the
5V-regulatory region of the AR gene. Together, these obser-
vations provide support to the idea that p53 negatively regu-
lates the transcription of AR gene in LNCaP cells.
Discussion
Expression of AR in PrECs contributes to increased cell pro-
liferation and survival [39,40]. Because androgen signaling
through AR activates transcription of genes that mediate the
cell growth regulatory functions of the AR [2,3,41,42], it is im-
portant to understand the molecular mechanisms that regu-
late expression of the AR gene and the activity of AR.
Regulation of AR activity in PrECs can be achieved in sev-
eral different ways [3,4]: modulation of AR gene expression,
androgen binding to AR, AR nuclear translocation, AR protein
stability, and AR transactivation. Importantly, studies have
provided evidence that a modest increase in AR mRNA was
the only change consistently associated with the development
of resistance to antiandrogen therapy [4,6]. Moreover, this in-
crease in AR mRNA levels and protein was both necessary
and sufficient to convert PC growth from a hormone-sensitive
to a hormone-refractory stage [6]. Furthermore, a study sug-
gested that the expression of gain-of-function mutants of p53
in LNCaP cells results in androgen-independent cell growth
[20]. Because mutations in the p53 gene are associated with
the progression of PC to advance stages [18–20], our obser-
vations provide support for the idea that mutations in p53 gene
in PC cells contribute to increased expression of AR and the
progression to androgen independence.
It has been noted that male p53-null mice have less apop-
tosis in the prostate glands that is associated with the first
4 days after castration compared to wild-type mice [43].
Moreover, expression of the transgene SV40 large T-antigen
in PrECs is known to result in adenocarcinoma of the mouse
prostate [44]. Because SV40 large T-antigen binds to p53
and inactivates it [7], it is conceivable that inactivation of p53
function by the large T-antigen in mouse PrECs, in part,
contributes to the upregulation of AR expression and the de-
velopment of adenocarcinoma of the prostate. Therefore,
further work will be needed to test this hypothesis.
Treatment of LNCaP cells with murine double minute-2
antagonist nutlin-3 downregulates the AR expression and
inhibits AR recruitment to promoters of the AR-responsive
genes [45]. Because nutlin-3 treatment of cells results in in-
creased levels of p53, our observations raise the possibility
that nutlin-3–mediated increased levels of p53 downregulate
the expression of AR, resulting in inhibition of recruitment of
AR to the promoters of AR-responsive genes.
Knockdown of p53 expression in LNCaP cells results in
upregulation of AR expression [46]. Therefore, our observa-
tions (Figure 3B) that knockdown of p53 in LNCaP cells re-
sulted in downregulation of p21CIP1, and upregulation of Bcl2
and AR are consistent with the above observations. Moreover,
we noted that levels of AR were detectable in HCT116p53/
cells, but not in isogenic HCT116p53+/+ cells. Together, these
observations support the idea that p53 negatively regulates
the expression of AR in LNCaP and HCT116 cells.
Previous studies have revealed that increased levels of
endogenous as well as exogenous p53 in PC cells lead to
growth inhibition and apoptosis in vitro and in vivo [19,
47–49]. Because expression of AR is important for the
proliferation and survival of PrECs [39,40] and increased
expression of AR is associated with androgen independence
Figure 6. p53 associates with the 5V-regulatory region of the AR gene. (A) A
comparison of the p53 DNA–binding site in the human AR gene with known
p53 DNA–binding sites in other genes. A bold nucleotide indicates a variation
from the p53 DNA–binding consensus sequence. (B) The 5V-regulatory re-
gion of human AR gene indicating the locations of the potential p53 DNA–
binding site (nucleotides 5290–5309), two primers that were used for PCR
(after chromatin precipitation), and the mRNA start site (nucleotide 5778) in
the AR gene (using the reference GenBank accession no. X78592). (C)
Chromatin was prepared from LNCaP cells either left untreated or treated
with etoposide (45 M for 15 hours). Chromatin was incubated with anti-
bodies to p53 (lanes 6 and 7) or, as a negative control, with an isotype
antibody (lanes 4 and 5). DNA was extracted from immunoprecipitates and
PCR-amplified using a pair of primers that flanked the p53 DNA–binding site
in the promoter region of the AR gene. As a positive control, we also amplified
the input chromatin DNA from control (lane 2) or etoposide- (lane 3) treated
cells. As a negative control, we did not add any DNA in the PCR (lane 1).
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[6], our observations provide support to the idea that the ex-
pression of functional p53 in normal PrECs and in PC cells by
negatively regulating the expression of AR also regulates cell
proliferation and survival [39,40]. Consistent with this idea,
we noted that forced expression of functional p53 in LNCaP
cells reduced cell proliferation (data not shown).
Treatment of LNCaP cells with high concentrations of
dihydrotestosterone (10 mM) downregulates the p53 mRNA
levels, whereas androgen deprivation of cells results in re-
duced levels of p53 protein [46]. Therefore, our observations
that increased levels of p53 in LNCaP cells negatively regu-
late the expression levels of AR mRNA and protein suggest
that there is mutual regulation of expression between p53
and AR.
Transcriptional activation by p53 requires the interaction of
the protein as a tetramer with a consensus binding site con-
sisting of two half sites, each comprising two copies of the
sequence PuPuPuC(A/T) arranged head-to-head and sepa-
rated by 0 to 13 bp [7]. In addition to the transcriptional
activation, p53 has been shown to repress the transcription
of certain genes [16,32,50]. Moreover, p53 is shown to re-
press the transcription of genes in human PC cells [51].
However, the molecular mechanisms for p53-mediated tran-
scriptional repression are complex and appear to depend on
the orientation of the p53 DNA–binding sequence (for ex-
ample, head-to-head vs head-to-tail orientation) and the pro-
moter context [15]. Interestingly, we report the presence of a
potential p53 DNA–binding site (a head-to-head site) in the
promoter region of the human AR gene. Moreover, we could
detect binding of p53 to the promoter region of the AR gene in
chromatin precipitation assays after treatment of LNCaP cells
with etoposide that resulted in stabilization of p53 and down-
regulation of AR levels. However, we could not detect the
binding of p53 to the promoter region in untreated LNCaP
cells. Therefore, our above observations make it likely that the
increased levels of p53 in LNCaP cells negatively regulate the
transcription of AR gene through binding to a head-to-head
p53 DNA–binding site in the promoter region. Because mo-
lecular mechanisms for transcriptional repression by p53 are
relatively very complex, further studies will be needed to deter-
mine how p53 represses the transcription of human AR gene.
In summary, our observations will serve basis to under-
stand themolecular mechanisms that contribute to increased
expression of AR in advanced human PCs.
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